Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

It's been a while since Clarkson nabbed a movie role as full-scale and invigorating as the one she has in "Lilly," a ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods Administration granted marketing ...

Two missing children and the people searching for them are facing difficult conditions due to the nature of the rural area where they were last seen.

Eli Lilly (NYSE: LLY) is encouraged by trial data for its latest weight-loss and diabetes medications. Where to invest $1,000 ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...